Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

Xponance Inc. raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 6.9% during the fourth quarter, ...

For this article, we used a Finviz screener to filter all the available ADR stocks. Then we compare the list with our Q4 2024 ...

Nothing drives down a drug’s price like competition. According the U.S. Food and Drug Administration (FDA), a drug’s ...

China's Xi urges global CEOs to protect trade as Trump tariffs loom China's President Xi Jinping urged a gathering of global CEOs on Friday to protect industrial and supply chains, as Beijing ...

Independent Advisor Alliance increased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.0% in the fourth ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

The analysis, which includes two studies looking into the benefits of revascularization in patients with ischemic LV dysfunction, highlights the efficacy of modern medical therapy when compared ...

If not treated, ATTRv-PN patients can lose sensation in their legs and feet. Credit: ljubaphoto via Getty Images. AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. When added to a ...